Advertisement

Ads Placeholder
Loading...

Emergent BioSolutions Inc.

EBS•NYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$8.23
$-0.15(-1.79%)
U.S. Market opens in 0h 55m

Emergent BioSolutions Inc. (EBS) Stock Overview

Explore Emergent BioSolutions Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap426.1M
P/E Ratio8.37
EPS (TTM)$0.93
ROE0.10%
Fundamental Analysis

AI Price Forecasts

1 Month$9.20
3 Months$9.90
1 Year Target$12.35

EBS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Emergent BioSolutions Inc. (EBS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 40.53, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $12.35.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8.37 and a market capitalization of 426.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.79%
5-Day Change
2.49%
1-Month Change
-7.74%
3-Month Change
-34.21%
6-Month Change
-10.05%
Year-to-Date (YTD) Change
-34.21%
1-Year Change
70.39%
3-Year Change
-15.93%
5-Year Change
-89.53%
All-Time (Max) Change
-29.66%

Contact Information

https://www.emergentbiosolutions.com
240 631 3200
400 Professional Drive, Gaithersburg, MD, 20879

Company Facts

9,000 Employees
IPO DateNov 15, 2006
CountryUS
Actively Trading

Frequently Asked Questions